7,575 Shares in Biogen Inc. $BIIB Acquired by North Dakota State Investment Board

North Dakota State Investment Board bought a new position in shares of Biogen Inc. (NASDAQ:BIIB) in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor bought 7,575 shares of the biotechnology company’s stock, valued at approximately $1,333,000.

A number of other institutional investors and hedge funds have also recently bought and sold shares of BIIB. Empowered Funds LLC increased its position in Biogen by 64.9% during the 1st quarter. Empowered Funds LLC now owns 7,054 shares of the biotechnology company’s stock worth $965,000 after purchasing an additional 2,777 shares in the last quarter. Focus Partners Wealth increased its position in Biogen by 172.2% during the 1st quarter. Focus Partners Wealth now owns 10,173 shares of the biotechnology company’s stock worth $1,392,000 after purchasing an additional 6,436 shares in the last quarter. Sivia Capital Partners LLC acquired a new stake in Biogen during the 2nd quarter worth approximately $216,000. Cerity Partners LLC increased its position in Biogen by 15.3% during the 2nd quarter. Cerity Partners LLC now owns 46,552 shares of the biotechnology company’s stock worth $5,847,000 after purchasing an additional 6,184 shares in the last quarter. Finally, NewEdge Advisors LLC boosted its holdings in Biogen by 13.4% in the 2nd quarter. NewEdge Advisors LLC now owns 2,673 shares of the biotechnology company’s stock worth $336,000 after acquiring an additional 316 shares during the period. Institutional investors and hedge funds own 87.93% of the company’s stock.

Analyst Ratings Changes

A number of equities analysts have weighed in on the company. Barclays assumed coverage on Biogen in a report on Thursday, February 19th. They issued an “equal weight” rating and a $185.00 price target for the company. Piper Sandler restated an “overweight” rating and issued a $225.00 price target (up from $214.00) on shares of Biogen in a report on Friday. The Goldman Sachs Group upped their price target on Biogen from $231.00 to $238.00 and gave the stock a “buy” rating in a report on Friday, April 24th. JPMorgan Chase & Co. upped their price target on Biogen from $175.00 to $185.00 and gave the stock a “neutral” rating in a report on Thursday, April 23rd. Finally, UBS Group upgraded Biogen from a “neutral” rating to a “buy” rating and upped their price target for the stock from $185.00 to $225.00 in a report on Wednesday, April 22nd. One analyst has rated the stock with a Strong Buy rating, fourteen have issued a Buy rating, thirteen have assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $215.62.

Biogen Stock Performance

Biogen stock opened at $190.56 on Wednesday. The stock has a market cap of $28.13 billion, a P/E ratio of 20.45, a price-to-earnings-growth ratio of 1.69 and a beta of 0.19. The company has a current ratio of 3.06, a quick ratio of 2.41 and a debt-to-equity ratio of 0.34. The stock has a 50 day moving average of $185.40 and a 200-day moving average of $180.14. Biogen Inc. has a 52 week low of $121.05 and a 52 week high of $205.97.

Biogen (NASDAQ:BIIB) last released its earnings results on Wednesday, April 29th. The biotechnology company reported $3.57 EPS for the quarter, beating the consensus estimate of $2.95 by $0.62. Biogen had a return on equity of 12.83% and a net margin of 13.81%.The company had revenue of $2.48 billion during the quarter, compared to analysts’ expectations of $2.29 billion. During the same period in the prior year, the business posted $3.02 EPS. The business’s revenue was up 1.9% on a year-over-year basis. Biogen has set its FY 2026 guidance at 14.250-15.250 EPS. On average, analysts expect that Biogen Inc. will post 14.18 EPS for the current fiscal year.

Biogen Company Profile

Biogen Inc is a multinational biotechnology company focused on discovering, developing and delivering therapies for neurological and neurodegenerative diseases. Headquartered in Cambridge, Massachusetts, the company has a longstanding emphasis on neuroscience, with research and commercial activities spanning multiple therapeutic areas including multiple sclerosis, spinal muscular atrophy and Alzheimer’s disease. Biogen was founded in 1978 and has grown into a global biopharmaceutical firm with operations and commercial presence across North America, Europe, Japan and other international markets.

The company’s marketed portfolio has historically included several well-known therapies for multiple sclerosis such as Avonex, Tysabri and Tecfidera, and it has pursued treatments for rare neurological conditions and genetic neuromuscular disorders.